Glycolipid antigens and autoantibodies in autoimmune neuropathies

Trends in Immunology

Volumn 34, Issue 9, 2013, Pages 453-459

  Willison, Hugh J ^a   Goodyear, Carl S ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Autoantibodies; B cell tolerance; Glycolipids; Guillain Barr syndrome; Molecular mimicry

Indexed keywords

AUTOANTIBODY; GLYCOLIPID;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN RECOGNITION; AUTOIMMUNE DISEASE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; NERVE MEMBRANE; NEUROPATHY; NONHUMAN; REVIEW;

AUTOANTIBODIES; B CELL TOLERANCE; GLYCOLIPIDS; GUILLAIN-BARRÉ SYNDROME; MOLECULAR MIMICRY;

ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; GLYCOLIPIDS; GUILLAIN-BARRE SYNDROME; HUMANS; MOLECULAR MIMICRY;

EID: 84883809663     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2013.05.001     Document Type: Review

References (64)

1. Milland J., Sandrin M.S. ABO blood group and related antigens, natural antibodies and transplantation. Tissue Antigens 2006, 68:459-466.
2. Bovin N., et al. Repertoire of human natural anti-glycan immunoglobulins. Do we have auto-antibodies?. Biochim. Biophys. Acta 2012, 1820:1373-1382.
3. Gehrs B.C., Friedberg R.C. Autoimmune hemolytic anemia. Am. J. Hematol. 2002, 69:258-271.
4. Chavada G., Willison H.J. Autoantibodies in immune-mediated neuropathies. Curr. Opin. Neurol. 2012, 25:550-555.
5. Kolter T., et al. Combinatorial ganglioside biosynthesis. J. Biol. Chem. 2002, 277:25859-25862.
6. Ledeen R.W. Ganglioside structures and distribution: are they localized at the nerve ending?. J. Supramol. Struct. 1978, 8:1-17.
7. Ledeen R.W., Yu R.K. Gangliosides: structure, isolation, and analysis. Methods Enzymol. 1982, 83:139-191.
8. Ledeen R.W., et al. The role of GM1 and other gangliosides in neuronal differentiation. Overview and new finding. Ann. N. Y. Acad. Sci. 1998, 845:161-175.
9. Kieseier B.C., et al. Autoimmune diseases of the peripheral nervous system. Autoimmun. Rev. 2012, 11:191-195.
10. Hughes R.A.C., Cornblath D.R. Guillain-Barré syndrome. Lancet 2005, 366:1653-1666.
11. Yuki N., Hartung H-P. Guillain-Barré syndrome. N. Engl. J. Med. 2012, 366:2294-2304.
12. Israeli E., et al. Guillain-Barré syndrome - a classical autoimmune disease triggered by infection or vaccination. Clin. Rev. Allergy Immunol. 2012, 42:121-130.
13. Willison H.J., Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 2002, 125:2591-2625.
14. Rinaldi S., Willison H.J. Ganglioside antibodies and neuropathies. Curr. Opin. Neurol. 2008, 21:540-546.
15. Kusunoki S., et al. Anti-Gal-C antibody in autoimmune neuropathies subsequent to mycoplasma infection. Muscle Nerve 1995, 18:409-413.
16. Young K.T., et al. Campylobacter jejuni: molecular biology and pathogenesis. Nat. Rev. Immunol. 2007, 5:665-679.
17. Fewou S.N., et al. Anti-ganglioside antibody internalization attenuates motor nerve terminal injury in a mouse model of acute motor axonal neuropathy. J. Clin. Invest. 2012, 122:1037-1051.
18. Kinsky S.C. Immunogenicity of liposomal model membranes. Ann. N. Y. Acad. Sci. 1978, 308:111-123.
19. Lloyd K.O., et al. Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition of the cells. Cancer Res. 1992, 52:4948-4953.
20. Kaida K-I., et al. Ganglioside complexes as new target antigens in Guillain-Barré syndrome. Ann. Neurol. 2004, 56:567-571.
21. Kaida K., et al. Anti-ganglioside complex antibodies associated with severe disability in GBS. J. Neuroimmunol. 2007, 182:212-218.
22. Kaida K., et al. GM1/GalNAc-GD1a complex: a target for pure motor Guillain-Barre syndrome. Neurology 2008, 71:1683-1690.
23. Kaida K., Kusunoki S. Antibodies to gangliosides and ganglioside complexes in Guillain-Barré syndrome and Fisher syndrome: mini-review. J. Neuroimmunol. 2010, 223:5-12.
24. Greenshields K.N., et al. The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice. J. Clin. Invest. 2009, 119:595-610.
25. Rinaldi S., et al. Combinatorial glycoarray. Methods Mol. Biol. 2012, 808:413-423.
26. -. J. Exp. Med. 2011, 208:67-80.
27. Durand C.A., et al. Phosphoinositide 3-kinase p110δ regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J. Immunol. 2009, 183:5673-5684.
28. Storry J.R., Olsson M.L. The ABO blood group system revisited: a review and update. Immunohematology 2009, 25:48-59.
29. Cooling L.W., et al. ABO typing discrepancies in children requiring long-term nutritional support: it is the gut after all!. Transfusion 2007, 47:10A.
30. Galili U. Immune response, accommodation, and tolerance to transplantation carbohydrate antigens. Transplantation 2004, 78:1093-1098.
31. Ang C.W., et al. The Guillain-Barré syndrome: a true case of molecular mimicry. Trends Immunol. 2004, 25:61-66.
32. Yuki N., Koga M. Bacterial infections in Guillain-Barré and Fisher syndromes. Curr. Opin. Neurol. 2006, 19:451-457.
33. Strid M.A., et al. Antibody responses to Campylobacter infections determined by an enzyme-linked immunosorbent assay: 2-year follow-up study of 210 patients. Clin. Diagn. Lab. Immunol. 2001, 8:314-319.
34. Bereswill S., et al. Novel murine infection models provide deep insights into the "ménage à trois" of Campylobacter jejuni, microbiota and host innate immunity. PLoS ONE 2011, 6:e20953.
35. Louwen R., et al. The sialylated lipooligosaccharide outer core in Campylobacter jejuni is an important determinant for epithelial cell invasion. Infect. Immun. 2008, 76:4431-4438.
36. Nyati K.K., et al. TH1 and TH2 response to Campylobacter jejuni antigen in Guillain-Barre syndrome. Arch. Neurol. 2011, 68:445-452.
37. Bowes T., et al. Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain-Barré syndrome. Infect. Immun. 2002, 70:5008-5018.
38. Goodyear C.S., et al. Monoclonal antibodies raised against Guillain-Barré syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J. Clin. Invest. 1999, 104:697-708.
39. Yuki N., et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:11404-11409.
40. Geleijns K., et al. Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain-Barré patients. J. Neuroimmunol. 2004, 150:132-138.
41. Kuijf M.L., et al. TLR4-mediated sensing of Campylobacter jejuni by dendritic cells is determined by sialylation. J. Immunol. 2010, 185:748-755.
42. Huizinga R., et al. Sialylation of Campylobacter jejuni lipo-oligosaccharides: impact on phagocytosis and cytokine production in mice. PLoS ONE 2012, 7:e34416.
43. Braun D., et al. IFN-alpha/beta enhances BCR-dependent B cell responses. Int. Immunol. 2002, 14:411-419.
44. Klaas M., et al. Sialoadhesin promotes rapid proinflammatory and type I IFN responses to a sialylated pathogen, Campylobacter jejuni. J. Immunol. 2012, 189:2414-2422.
45. Willison H.J., Veitch J. Immunoglobulin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller Fisher syndrome. J. Neuroimmunol. 1994, 50:159-165.
46. Geleijns K., et al. HLA class II alleles are not a general susceptibility factor in Guillain-Barré syndrome. Neurology 2005, 64:44-49.
47. + T cells but not CD1 or NKT cells. Immunol. Cell Biol. 2011, 89:502-510.
48. Cobb B.A., et al. Polysaccharide processing and presentation by the MHCII pathway. Cell 2004, 117:677-687.
49. Le Bourhis L., et al. Mucosal-associated invariant T cells: unconventional development and function. Trends Immunol. 2011, 32:212-218.
50. Matsumoto Y., et al. BAFF aids generation of IgG anti-ganglioside antibodies in response to Campylobacter jejuni lipo-oligosaccharide. J. Neuroimmunol. 2010, 218:67-72.
51. Puga I., et al. B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nat. Immunol. 2011, 10.1038/ni.2194.
52. Kuijf M.L., et al. Origin of ganglioside complex antibodies in Guillain-Barré syndrome. J. Neuroimmunol. 2007, 188:69-73.
53. Mauri L., et al. Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a. Glycobiology 2012, 22:352-360.
54. Hakomori S., Handa K. Glycosphingolipid-dependent cross-talk between glycosynapses interfacing tumor cells with their host cells: essential basis to define tumor malignancy. FEBS Lett. 2002, 531:88-92.
55. Varki A. Selectin ligands. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:7390-7397.
56. Pestronk A., et al. Multifocal motor neuropathy: serum IgM binding to a GM1 ganglioside-containing lipid mixture but not to GM1 alone. Neurology 1997, 48:1104-1106.
57. Gregson N.A., et al. Acute motor neuropathy with antibodies to GM1 ganglioside. J. Neurol. 1991, 238:447-451.
58. Townson K., et al. Sulfatide binding properties of murine and human antiganglioside antibodies. Glycobiology 2007, 17:1156-1166.
59. Zitman F.M., et al. Neuropathophysiological potential of Guillain-Barré syndrome anti-ganglioside-complex antibodies at mouse motor nerve terminals. Clin. Exp. Neuroimmunol. 2011, 2:59-67.
60. Galban-Horcajo F., et al. Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy. Eur. J. Neurol. 2013, 20:62-70.
61. Addadi L., et al. Two and three-dimensional pattern recognition of organized surfaces by specific antibodies. Acc. Chem. Res. 2008, 41:254-264.
62. Scheffer L., et al. Antibody labeling of cholesterol/ceramide ordered domains in cell membranes. Chembiochem 2007, 8:2286-2294.
63. McAlarney T., et al. Specificity and cross-reactivity of anti-galactocerebroside antibodies. Immunol. Invest. 1995, 24:595-606.
64. Rinaldi S., et al. Combinatorial glycoarray detects diverse new antibody specificities in Guillain-Barre syndrome. Presented at the J Neurol Neurosurg Psychiatry: Association of British Neurologists Annual Meeting 2012.